Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Collaboration on the discovery and the development of new drug targets and candidates for CNS diseases

04.02.2002


GENOPIA Biomedical LLC (GENOPIA), a biotechnology firm headquartered in Saarbücken, Germany and Ciphergen Biosystems, Inc. (Nasdaq: CIPH) in Fremont, CA, will collaborate on the discovery and the development of new drug targets and candidates for CNS diseases. GENOPIA Biomedical focuses on the development of novel drug candidates and uses advanced proteomics as its main drug discovery and high-throughput screening tool, while Ciphergen Biosystems is a world leader in the development of proteomics technology, most notably its SELDI (Surface-Enhanced Laser Desorption/Ionization) ProteinChip® technology. The close collaboration between GENOPIA and Ciphergen reflects the growing importance of proteomics in modern drug discovery. Plans include the joint development of highly customized ProteinChip® surfaces to meet GENOPIA ’s needs for its proprietary drug targets.

Drs. Bernhard Schu (CEO) and Helge Völkel (CSO) of GENOPIA , commented on the collaboration between the two companies: "Stroke is one of the most common neurological conditions, and represents one of the largest pharmaceutical markets in the 21st century. Scientists at GENOPIA have identified proteins that play key roles in the cellular response to hypoxia and hypoxia-reperfusion injury, key components of stroke. In a mouse model of stroke, we were able to demonstrate the importance of these target proteins. The use of specially adapted, state-of-the-art Ciphergen ProteinChip® technology will greatly accelerate our drug discovery process, and also allow us to shorten the time to further characterize our already identified drug candidates."

Drs. Bernhard Schu and Helge Voelkel continued "The objective is to accelerate protein biology research, with the same ease and success in which genomic and molecular biology research is done today. We envision new products that combine the expertise of both companies to create rapid ‘gene to protein’ transcription, translation, and protein purification capabilities at various scales, tagged or tag-free, as well as advanced ‘on-chip’ molecular-interaction and cellular assay platforms that further enable functional genomics."



This press release contains statements on planned developments. The release reflects the intentions and opinions of GENOPIA Biomedical and Ciphergen, Inc., at the time of the release. This release is not be construed as a binding statement by either company.

| GENOPIA

More articles from Life Sciences:

nachricht Cells communicate in a dynamic code
19.02.2018 | California Institute of Technology

nachricht Studying mitosis' structure to understand the inside of cancer cells
19.02.2018 | Biophysical Society

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Contacting the molecular world through graphene nanoribbons

19.02.2018 | Materials Sciences

When Proteins Shake Hands

19.02.2018 | Materials Sciences

Cells communicate in a dynamic code

19.02.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>